Browse by author
Lookup NU author(s): Dr Pearlin TeowORCiD, Henry Cain, Professor Adam ToddORCiD, Dr Mark Turner, Professor Linda SharpORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY. Published by BMJ Group.INTRODUCTION: Breast cancer is the most common cancer in women in the UK. For women who have early-stage oestrogen-receptor positive (ER+ve) disease, daily oral adjuvant endocrine therapy reduces risk of recurrence. Recently, CDK4/6 inhibitors, a form of biological therapy, have been approved for use alongside endocrine therapy. However, trial data suggest there may be challenges with adherence to CDK4/6 inhibitors. This study aims to explore the experiences of adherence and support needs of women who have been prescribed CDK4/6 inhibitors for early ER+ve breast cancer. It will also co-develop an intervention to support women with adherence to these drugs alongside endocrine therapy through an evidence-based, theory-informed and patient-centred approach. METHODS AND ANALYSIS: The SWEET-PLUS study has three phases. Phase I uses semi-structured interviews or focus groups to explore the experiences of women with early breast cancer who have been prescribed CDK4/6 inhibitors. It will also explore their support needs and experiences of adherence. Phase II involves interviews or focus groups with healthcare professionals who support CDK4/6 inhibitor prescription and associated care to understand the existing support and unmet needs. Phase I and II findings will inform phase III, which comprises workshops and user testing interviews to co-develop an intervention to support women with adherence to CDK4/6 inhibitors alongside endocrine therapy. This will be delivered as an additional module prototype designed for future integration into the existing HT&Me intervention, which supports women with adherence to endocrine therapy.Data from phases I and II will be analysed using a framework approach-based thematic analysis. Phase III data will be analysed through content analysis. ETHICS AND DISSEMINATION: SWEET-PLUS received ethical approval from the National Health Services (NHS) Health Research Authority (Cambridge East Research Ethics Committee (25/EE/0220)). Research findings will be disseminated through peer-reviewed journal articles and via international and national conferences. Further dissemination will be guided by patient and public involvement.
Author(s): Teow P, McGeagh L, Cain H, Todd A, Rehman F, Brett J, Levitt N, Turner M, Stewart S-JF, Hunt E, Terrado H, Watson E, Sharp L
Publication type: Article
Publication status: Published
Journal: BMJ open
Year: 2026
Volume: 16
Issue: 8
Online publication date: 11/08/2026
Acceptance date: 10/07/2026
Date deposited: 25/08/2026
ISSN (electronic): 2044-6055
Publisher: BMJ Group
URL: https://doi.org/10.1136/bmjopen-2026-119558
DOI: 10.1136/bmjopen-2026-119558
Data Access Statement: No data are available. Data sharing is not applicable at this stage as this manuscript describes a study protocol, and we are still in the process of data collection. Upon completion of the study, de- identified data will be made available in accordance with institutional policies, participant consent, and ethical approvals.
PubMed id: 42580839
Altmetrics provided by Altmetric
